|
| |
Casodex
Additional studies by Nazareth and Weigle 22 ; demonstrated that the AR can be activated by a protein kinase A activator in the absence of androgen 22 ; . This activation can be blocked by a protein kinase A inhibitor peptide and the AR antagonists casodex and flutamide, indicating that the activation effect was due to PKA and dependent on AR. More recently it has been demonstrated that neuropeptides, which activate PKA, sensitize prostate cancer cells to signaling by peptide growth factors, such as EGF 6 ; . Thus, we propose that during prostate cancer progression and androgen ablation therapy, there may be a microenvironment in which peptide growth factors and neuropeptides activate signal transduction pathways that influence AR activity and help drive prostate cancer cells to an androgen-independent state. Our observation of elevated levels of activated MAP kinase in advanced prostate tumors begins to address the mechanism of androgen-independent growth of prostate tumors cells and suggests potential targets for blocking or reversing progression to androgen independence. Acknowledgments.
Treatment option in the target population. These benefits, in context with the tolerability profile established for CASODEX 150 mg in the EPC program, provide a better understanding of the CASODEX risk-to-benefit paradigm and support its expanded use. The changing prostate-cancer knowledge base remains a backdrop against which treatment options and strategies must be evaluated. The option of using CASODEX as adjuvant therapy in high-risk patients or as an alternative to watchful waiting fits into the current web of approved treatment strategies for reasons of efficacy, when compared with placebo; for reasons of potential benefit, when compared with medical or surgical castration; and for reasons of demonstrated tolerability.
Table 1 Effect of ICI 182, 780 and Casodex, alone or in combination, on body weight, uterine weight and LGR. Results are means Sham + vehicle Body weight g ; Uterine weight mg ; LGR m day ; 27575 54218 1023 * 039 Ovx + vehicle 33613 17591 1767 * 1488 * 040 * Sham + ICI 182, 780 28038 * 037 Sham + ICI 182, 780 + Cwsodex 27700 18760 1080 * 060.
Bilateral ovariectomy and placebo pellets of 1.5 and 5 mg, respectively, inserted subcutaneously. Experiment II. Six-month-old animals, with an average weight of 270 g range 252290 g ; , were subjected to ovariectomy or a sham operation as described above. At this age, the animals exhibit imperceptible growth 13 ; . Ten animals were included in each of the following groups: group 1, sham OVX; group 2, OVX plus placebo pellet; group 3, OVX plus ADIONE 1.5-mg slow-release pellet group 4, OVX plus Casodwx kindly provided by Dr. B. M. Vose, Zeneca Pharmaceuticals, Macclesfield, UK group 5, OVX plus ADIONE 1.5-mg pellet ; and Casodex; group 6, OVX plus Arimidex kindly provided by Dr. Vose and group 7, OVX plus ADIONE 1.5-mg pellet ; and Arimidex. Cssodex 5 mg kg 1 day 1 ; and Arimidex 0.1 mg kg 1 day 1 ; were both dissolved in water and administered orally. Calcein 30 mg kg, Sigma Chemicals, Dorset, UK ; and tetracycline hydrochloride 25 mg kg, Lederle Laboratory, Gosport, Hants, UK ; were injected intraperitoneally 14 and 7 days before each group of animals was killed. Cardiac puncture was performed under anesthesia, and plasma samples were stored at 70C until required. The animals were then killed by cervical dislocation after periods of 21, 60, 90, and 180 days in experiment I and after 90 days in experiment II. The uteri were removed and weighed, and ovariectomy was confirmed by the absence of ovarian tissue. The tibiae were cleaned of soft tissue, fixed in 70% alcohol for 24 h, dehydrated through graded alcohols, and embedded without decalcification in London Resin London Resin, Basingstoke, Hants, UK ; . Longitudinal sections of the proximal metaphysis were cut using a Reichart-Jung microtome Leica, Germany ; . Sections 5 m ; were stained with toluidine blue, and 12-m unstained sections were cut for fluorescent microscopy. Bone histomorphometry was performed using transmitted and epifluorescent microscopy linked to a computer-assisted image analyzer Seescan, Cambs, UK ; . Bone volume and surface parameters were measured by tracing the relevant features with a cursor on the video screen. Cancellous bone volume BV TV ; measurements were performed at 40 magnification, and the surface parameters were measured at 400 magnification. All sections were analyzed without knowledge of the group from which they came. BV TV at the proximal metaphysial cancellous bone from animals killed on days 21 and 60 was measured on two nonconsecutive sections, and four nonconsecutive sections were analyzed from animals killed on days 90, 120, and 180. The latter was done because of the relative lack of bone spicules in OVX rats. A standard area of 2 mm2 at least 2 mm from growth plate to exclude primary spongiosa ; was measured. Trabecular number and thickness were calculated as previously described 20 ; . Static parameters were measured in the same way as that described for BV TV and included osteoblast surface, osteoclast surface, and osteoclast number. Longitudinal growth rate LGR ; was derived by measuring the distance between the tetracycline and calcein fluorescent bands that parallel the growth plate at four equally placed sites per section and dividing by the time interval between the two injections. The bone formation rate BFR; tissue level, total surface referent ; was calculated from the product of the percentage of the trabecular bone surface with a double fluorochrome label and the mineral apposition rate MAR ; : the former was obtained by measuring the percentage of the trabecular bone surface, covered by two fluorochrome labels, and the latter by dividing the interlabel distance by the time interval between the injections of the labels in the corresponding area. The BFR values were not corrected for label escape.
McLeod DG. Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist 1997; 2: 18-27. This review compares the tolerability profiles of the three currently available non-steroidal antiandrogens flutamide, CASODEX [bicalutamide] and nilutamide ; . Gynaecomastia and breast pain occurred more frequently during antiandrogen monotherapy than during combination therapy or castration. Gastrointestinal symptoms and hepatotoxicity were common to all three drugs, but diarrhoea occurred more frequently with flutamide and reversible hepatitis fatal fulminant hepatitis have been reported with nilutamide and flutamide. Other adverse events associated with nilutamide were interstitial pneumonitis, delayed adaption to darkness after exposure to bright light, and alcohol intolerance. The author concludes that CASODEX may offer some tolerability advantages over flutamide and nilutamide.
Casodex without prescription
Refractory follicular NHL. On December 18, 2002, the committee will discuss new drug application NDA ; 20498, S012, CASODEX 150 milligrams bicalutamide ; , AstraZeneca Pharmaceuticals LP, indicated as: 1 ; Adjuvant therapy to radical prostatectomy and radiotherapy of curative intent in patients with locally advanced nonmetastatic prostate cancer who have a high risk for disease recurrence, or 2 ; immediate treatment of localized nonmetastatic prostate cancer in patients for whom therapy of curative intent is not indicated. Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by December 10, 2002. Oral presentations from the public will be scheduled between approximately 1: 15 p.m. and 1: 45 p.m. on December 17, 2002, and between approximately 8: 15 a.m. and 8: 45 a.m. on December 18, 2002. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before December 10, 2002, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the time requested to make their presentation. After the scientific presentations, a 30-minute open public session may be conducted for interested persons who have submitted their request to speak by December 10, 2002, to address issues specific to the topic before the committee. Background materials for this meeting will be posted at the Oncologic Drugs Advisory Committee Dockets Web site at : fda.gov ohrms dockets ac acmenu . Click on the year 2002 and scroll down to the Oncologic Drugs Advisory Committee meetings. ; The background materials for BEXXAR will be posted on December 16, 2002, and the background materials for CASODEX will be posted on December 17, 2002. The slides and transcripts from the meeting will be posted at this same web address about 3 weeks after the meeting. Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to and ultracet.
He sent me to a pain management doctor and she wanted me on vicodin.
Like you'd expect, the psychopharmacology of cannabinoids is complex, and there is some concern about depression caused by the drug and lioresal.
Based on these analyses, it appears that the reductions in the proportion of patients with bone scan confirmed disease progression or death in the Casodes treatment groups in Trials 24 and 25 were statistically significant. However, The actual reductions in the proportion of patients with disease progression or death, however, were relatively small and were 3.1% Trial 24 ; and 6.8% Trial 25 ; . The differences between the treatment groups are a result of a reduction in bone scan confirmed disease progression and not improved survival as shown by the data in Table 4 Because the studies are immature relative to anticipated survival with a median follow up of approximately 3 years, the long-term clinical significance of these modest reductions in bone scan confirmed disease progression is unknown at this time. To obtain a more complete picture of which treatment subgroup s ; may have derived benefit from treatment with Casodex, the Sponsor was asked to provide additional subgroup analyses based on the patient's treatment prior to randomization i.e., radical prostatectomy, radiotherapy, or management by watchful waiting ; . The descriptive analyses for each of the trials are summarized in Table 6, Table 7, and Table 8. For each of the trials, the proportion of patients with bone scan confirmed disease progression or death from any cause in the absence of disease progression was numerically lower in Casodex-treated patients in each of the subgroups.
At 96 weeks, patients receiving CASODEX 150 mg maintained baseline bone mineral density in both the lumbar spine and hip + 2.42% [95% CI 0.70, 4.14] and + 1.13% [95% CI -0.03, 2.30], respectively ; , whilst patients receiving medical castration showed a progressive decrease -5.40% [95% CI -6.86, -3.94] and -4.39% [95% CI -6.02, -2.76], respectively ; Figure 17 ; .40 The difference between the two treatment groups for the lumbar spine was statistically significant at all time points 24, 48, 72 and 96 weeks, p 0.0002 at Week 24; p 0.0001 at all other time points ; Figure 17a ; .40 The difference between the two treatment groups for the hip was statistically significant at 48, 72 and 96 weeks p 0.0001 ; Figure 17b ; .40 and robaxin.
A sensation of fullness or pressure in one or both ears.
Detect the mobility shift commonly associated with activating Ras mutations 49 ; , suggesting that mutational activation of c-Ras was not responsible for the acquired tumorigenicity of these cells data not shown ; . Thus, it is plausible that chronic paracrine signaling may mediate activation of MAPK in vivo in cells overexpressing c-Ras. Acquisition of Androgen Hypersensitivity. We found that activation of Ras MAPK signaling diminished but did not replace the requirement of LNCaP cells for androgen. LNCaP cells expressing Ras T35S or E37G were able to grow robustly at concentrations of androgen that were 12 orders of magnitude lower than the 10 9 M that were required by the parental LNCaP cells. However, reduction of androgen to 10 12 resulted in growth arrest even for the Rasexpressing cells. Comparable results were obtained whether measuring adherent or nonadherent growth. Thus, these cells have become hormone hypersensitive rather than hormone independent. A similar phenomenon was observed when measuring PSA production, consistent with previous results showing that the PSA promoter can be dually regulated by signal transduction pathways in addition to androgens 50 54 ; . expected, we found that steady state endogenous cellular PSA was dramatically elevated in the RasT35S and RasE37G stable cell lines. Northern analysis confirmed up-regulated PSA mRNA expression in both of these cell lines. However, as with the growth response, PSA expression diminished when androgen levels were reduced to 10 12 less. We additionally demonstrated that the antiandrogen Caodex and the MEK inhibitor U0126 were each able to attenuate the elevated endogenous PSA levels in RasT35S and RasE37G cell lines, highlighting the cross-talk between Ras directed signaling pathways and AR-dependent gene expression. Thus, Ras signaling did not bypass the requirement for steroid of this androgen-dependent gene expression. Rather, Rasmediated signaling cascades apparently converted the normal regulatory machinery to an androgen hypersensitive state. The Role of the AR in Ras-expressing Cells. The fact that Ras signaling did not eliminate the steroid requirement of LNCaP cells is consistent with the concept that hormone refractory prostate cancer still requires the AR 55, 56 ; . This is reflected in the fact that retention, overexpression, and mutation of ARs are common in tumors that are unresponsive to hormone ablation. More recent reports have demonstrated that knockdown of the AR by hammerhead ribozyme, antibody 57 ; , or antisense 58, 59 ; blocks prostate cancer cell growth. How could signal transduction sensitize the AR to steroids? In the case of the estrogen receptor, several reports demonstrate that signaltransducing kinases can directly phosphorylate the steroid receptor and decrease or eliminate the requirement for estrogen 60 ; . However, we recently have mapped the major phosphorylation sites on the AR 61 ; , and suspect that none of them is sufficient for regulating the transcriptional activation of the AR. On the other hand, several transcriptional coregulators have been shown to be targets of Ras-related signal transduction. In addition, recent reports point to overexpressed transcriptional coactivators as regulators of androgen sensitivity in advanced disease 62 65 ; . suspect that these coactivators may be major targets of signaling pathways that regulate androgen dependence. Clinical androgen ablation therapy reduces but does not eliminate androgen from the circulation 66 ; . Residual steroid creates conditions favorable for selection of cancer cells having the ability to proliferate under reduced levels of androgen. Compensatory mechanisms that allow growth in castrate levels of androgen include overexpression or mutation of the AR 55, 56 ; , overexpression of transcriptional coregulators 62, 65 ; , and, as shown by us 32 ; , activation of Ras signaling. These mechanisms are not mutually exclusive but are likely to be mutually reinforcing. Taken together, our findings show that chronic activation of Ras by and zanaflex.
Thanks - 0 ratings & reviews sign in to rate posted am edt ; on by alex5 add to friends send message report abuse i posted this question originally in february of this year.
BOOK REVIEWS Vitamins. Wilhelm Friedrich, ed. Reviewed by Robert B. Rucker . Dietary Restriction and Aging. David L. Snyder, ed. Reviewed by Roy L. Walford Impact of Helminth Infections on Human Nutrition. Lani S. Stephenson and Celia Holland, eds. Reviewed by Carol I. Waslien Perinatal Nutrition. B. S. Lindblad, ed. Reviewed by Sheri Zidenberg-Cherr Drug-Nutrient Interactions. T. K. Basu, ed. Reviewed by Wayne R. Bidlack Proceedings of the Fifty-Third Annual Meeting of the American Institute of Nutrition Erratum Announcements 1744 1745 1746 and skelaxin.
History of Casodex
For over a decade now, clinical and experimental researchers have hunted for gene polymorphisms as a major cause of hypertension, coronary artery disease CAD ; or heart failure, such as angiotensin-converting enzyme ACE ; polymorphisms, which were accused to be a major contributor of cardiovascular diseases 1, 2 ; . Sequence variants of the components of the renin-angiotensin-aldosterone system were suggested to have significant influences on cardiovascular homeostasis 2, 3 ; . Both gene targeting and studies using transgenic mice suggested a critical role of the ACE gene in blood pressure regulation. Moreover, since an up-regulation of myocardial ACE gene expression has been observed See page 1957 in patients with heart failure, the ACE gene was one of the favorites within the known gene polymorphisms and a top candidate for cardiovascular researchers. Over 100 of basepair bp ; switches, insertions I ; or deletions D ; were identified within the ACE-gene but only a few, namely the ACE I D, D D, or polymorphisms seemed to have a significant impact on either CAD, hypertension or restenosis following coronary stenting CS ; . The ACE I D polymorphism of a 287-bp Alu element within the intron 16 of the ACE gene has attracted significant attention and has been extensively investigated in a spectrum of cardiovascular phenotypes because of its positive correlation with serum ACE activity 4 ; . In addition, several studies showed a positive association between the ACE D D genotype and an increased risk of myocardial infarction 2 ; . Yet the association for hypertension, left ventricular hypertrophy, cardiomyopathy, CAD and restenosis after percutaneous transluminal coronary angioplasty remains controversial 4 6 ; . Even meta-analysis of several studies, statistical mimicries and studies in very selected patients populations provided a rather confusing puzzle of results which ultimately leaves it to the individual researcher, clinician, and journal.
Replaced AR with these receptors in our CAT assay. Because it is known that Adiol can bind directly to the ER and functions as an estrogen 1, 47 ; , we also tested the effect of Adiol on ER transcriptional activity using a reporter, ERE-CAT. As shown in Fig. 7, MMTV-CAT activity was induced significantly only via AR, but not progesterone receptor or glucocorticoid receptor, in the presence of ARA70 and Adiol. As expected, ERE-CAT activity could also be induced by Adiol, with the induction fold similar to that achieved by 10 8 E2. These results suggest that Adiol possesses AR-mediated androgenic activity as well as ER-mediated estrogenic activity and can activate the estrogen target gene via ER. HF and Casodex Fail to Block Adiol-Induced AR Transcriptional Activity. The treatment of advanced stages of prostate cancer, the most commonly diagnosed noncutaneous malignancy in the United States, and the second leading cause of cancer death in North American men, with so-called ``total androgen blockage, '' with a combination of surgical or medical castration with antiandrogen, such as casodex or HF, still has very limited effectiveness 22 ; . Most of the patients will no longer respond to this therapy within 1824 months of treat and tegretol.
Casodex ingredients
Amrol D, Keitel D, Hagaman D, Murray J. Vanderbilt University, Nashville, Tennessee, USA. damrol gw.mp BACKGROUND: Contact dermatitis is a common clinical problem, with prevalent sensitizers being cosmetics, metals, medicines, and plants. Plants of the Toxicodendron species cause allergic contact dermatitis ACD ; in 50% to 70% of the population. Pimecrolimus is an ascomycin macrolactam developed for the treatment of inflammatory skin diseases and approved by the US Food and Drug Administration for atopic dermatitis. There are studies supporting the effectiveness of macrolactams when administered before antigen challenge, but there are no studies describing the effectiveness of these drugs in the treatment of established human ACD. OBJECTIVE: To investigate the effect of topical pimecrolimus in the treatment of Toxicodendron-induced ACD once rash is evident. METHODS: Poison ivy tincture was applied to the bilateral anterior forearms of 12 subjects with Finn Chambers Allerderm Diagnostic Products, Petaluma, CA ; . After dermatitis was evident, volunteers treated each arm twice daily with either 1% topical pimecrolimus cream or placebo in a blinded fashion. Outcomes measured were a dermatitis grading score and time to rash and itch resolution. RESULTS: The median + - SEM time for rash resolution was 16.55 + - 1.59 days in the treatment group and 16.27 + - 1.82 days in the placebo group P 0.601 ; . The median time for itch resolution was 4.73 + - 1.56 days in the treatment group and 4.91 + - 1.59 days in the placebo group P 0.167 ; . The average dermatitis score was 2.26 + - 0.17 in the treatment group and 2.32 + - 0.15 in the placebo group P 0.62 ; . CONCLUSIONS: The application of topical pimecrolimus is ineffective in the treatment of ongoing Toxicodendron-induced ACD.
| Discount Casodex onlineAn option presented itself that made sense when the risk-reward discussion took place. My clinical experience allowed me to share other patient success stories using the CDM concept. Together we created and accepted a treatment strategy that was intended to minimally stabilize the cancer disease process. I made it very clear that we were in this together and I was as close as a telephone call. He could count on me as brother as I was confident we could make a difference. Based on his heightened disease status and dangerous Gleason Score, I elected to start him on a CDM protocol that included various mechanisms of action to suppress the disease or make it less aggressive or even dormant. Without going into a lot of detail here, he was placed on a patented prostatitis formula called, Peenuts. This is a synergistic blend of vitamins, minerals, herbs, and amino acids that has shown the unique ability to resolve the signs and symptoms of prostatitis. This was an important step as prostatitis has been shown to evolve into prostate cancer by many research experts including the American Association of Cancer Research AACR ; and David Bostwick, M.D., world renowned Pathologist. Carl was also started on Avodart at 0.5 mg daily to decrease the conversion of Testosterone to Dihydrotestosterone DHT ; as well as promote an anti-angiogenic component decreases new blood vessel formation ; while reducing the size of the prostate. He knew full well that the PSA would be decreased by some number less than half based on the presence of benign prostatic hyperplasia cells and cancer cells. I was also cognizant of the benefit demonstrated by the Prostate Cancer Prevention Trial PCPT ; where this class of drug Avodart or Proscar ; was associated with a decreased incidence of prostate cancer by 25% when compared to placebo. While I had no data to show specific benefit versus prostate cancer with this drug, I did not want the cancer to be exposed to DHT, the more desirable form of the cancer growth promoting male hormone. Vitamin D3 the active form of Vitamin D ; was added for its benefit in decreasing prostate cancer cell proliferation. Additionally, Omega 3 fatty acids were added to enhance the Omega 6: Omega 3 fatty acid ratio, thereby, enhancing heart health and a possible mechanism versus prostate cancer. The modified Mediterranean Diet was the diet of choice rationale for this diet will be discussed comprehensively in the diet section ; . The last integral piece of the treatment strategy was the use of Casodex Bicalutamide ; , a non-steroidal antiandrogen, used at 150 mg per day, similar to the dose effectively used in Europe. I have had tremendous experience using Casodex at the aforementioned dose as a monotherapy. This represents a higher dose than that typically used in the United States but is quite safe and effective when used intermittently. Specifically, the anti-androgen blocks the prostate cancer cell receptor, thereby, inhibiting the growth of cancer. To state this differently, Testosterone, which remains normal to high in this treatment scenario, is preferentially blocked from its usual action of attaching to the cell receptor in the presence of the antiandrogen. The concept is analogous or similar to what you would expect to see when you put plastic child safety caps on an electrical outlet. No matter how hard you try to connect the cord of a lamp as example ; to the source of electricity, you can't do it. Thusly, Casodex blocks the interaction of DHT with the cell receptor and promotes cell death preferentially over cell growth and baclofen.
39.99 The latest developments including genetics clearly explained.
10 ; i have been reading how migraines is one of the symptoms of dysautonomia and toradol.
|
Dr. Hoberman, the re-reads indeed showed no evidence of any bias in the local reading of bone scans between Casodex and placebo treated patients. And, therefore.
Patterns of relief of associated symptoms paralleled those of pain relief and carisoprodol and Buy cheap casodex online.
Reported performance Oncology sales increased by 13% to reach , 819 million in 2007, compared with , 262 million in 2006. Underlying performance Excluding the effects of exchange, Oncology sales grew by 8%. Arimidex sales reached , 730 million, up 10%. In the US, sales of Arimidex rose by 13% to 4 million. Total prescriptions for Arimidex increased nearly 5.3% compared with 1.3% growth in the market for hormonal treatments for breast cancer. Arimidex sales in other markets increased by 8% to , 036 million. Sales for the full year were up 6% in Western Europe and increased 9% in Japan. Casodex sales increased by 6% to , 335 million. Sales in the US for the full year were up 1% to 8 million. Sales in other markets, which account for more than 75% of product sales, were up 8%, on 6% growth in Western Europe and 13% sales growth in Japan. Iressa sales were unchanged for the full year. Sales in Japan increased 4% for the year; sales in China were up 24%. Faslodex sales increased 10% to 4 million for the full year, on growth of 3% in the US and 18% sales growth in other markets.
Gen may cause endocarditis, soft tissue abscess, and periodontitis in humans. However, infection of other rare sites has recently been reported, including brain abscess, thyroid and trental.
The nurse said she could suck it out, but it would only prolong the process.
Casodex cost
Committee members said release of the report, which was described in the oct.
Phrenia by tasks containing relatively many idioms. Methods: 10 male subjects with schizophrenia were tested on 2 kinds of idiom tests; multiple-choice task choose 1 of 5 words to make the sentence complete with idiomatic expression, 338 idioms ; and completion task write down a word to make the sentence meaningful with idiomatic expression, 278 idioms ; . Results: Results on the multiple-choice task are better than those on the completion task in all participants. Some near- ; significant correlations were observed between task results and some characteristics of the subjects. Conclusion: The multiple-choice task may require less lexicalization than the completion task. General language ability is well correlated with idiom comprehension, which may indicate the nonspecific processing of idioms. Idioms could be taught for people with schizophrenia, which enables them to use language more fluently and to participate in daily life.
Policy Guide, it seems likely that, for the most part, prescription drugs imported under the MMA will fall into the exception to the requirement under section 355 for repackaging to be covered by an FDAapproved drug application. If, however, Congress amended the MMA to allow importation of other dosage forms, persons wishing to repackage those drugs would need an NDA to do so, unless Congress modified these statutory requirements with respect to imported drugs.
And how much casodex or any hormonaltherapy alters that natural history is debatable and buy ultracet.
The first usage of glossary terms are bolded in the text. ; Adjuvant Assisting or aiding. Used to describe additional treatments administered in addition to a definitive therapy. For EBRT this usually refers to androgen deprivation given after ERBT is finished. Androgen A hormone with masculinizing properties, i.e. testosterone. Androgens stimulate growth of both normal prostate and most malignant prostatic cells. Androgen deprivation A therapeutic strategy designed to decrease circulating levels of the male androgen testosterone and its related compounds. Androgen deprivation can be done by removing the organs that produce testosterone i.e. removing the testicles; orchiectomy ; or by giving medication see hormone therapy ; . Anti-androgen Oral agents flutamide Eulexin ; and bicalutamide Casodex ; that block the action of testosterone and its active metabolite dihydrotestosterone DHT ; at the cellular level by interfering with androgenreceptor interactions. Applicator A device used to deliver or hold a radioactive source during brachytherapy. Benign prostatic hyperplasia BPH ; Non-cancerous enlargement of the prostate gland, which often results in difficulty with urination. The incidence increases with age. Biopsy Sampling of tissue. Blocks Pieces of metal alloy that can be used to shape the EBRT beam. Bone scan A nuclear medicine imaging study that utilizes a radioactive compound injected into a vein to identify areas of increased bone cell activity in the skeleton; used to screen for the presence of bone metastases. Boost An additional dose of radiation that is given after an initial course of treatment, to enhance tumor control. Brachytherapy In radiation therapy, treatment with ionizing radiation that is applied directly into an organ that has cancer. For prostate cancer, this consists of implantation of radioactive material into the prostate. Also called implants or seeds. Cancer A group of diseases characterized by uncontrolled cell growth. Cancer cells, unlike benign cells, exhibit the properties of invasion and metastasis. Catheter A general term for a tube that is inserted to drain fluids from or instill fluid into the body. Cell The fundamental structural and functional unit of living organisms. Centigray cGy ; The measurement of radiation delivered to a tumor. A gray Gy ; is a unit of absorbed energy dose. Clinical trial, Phase 1 A clinical trial designed to determine the appropriate dose and toxicities of an investigational agent or treatment. Clinical trial, Phase 2 A clinical trial designed to determine the effectiveness and side effects of an investigational agent or regimen. Clinical trial, Phase 3 A clinical trial designed to test the effectiveness of a given treatment as compared to existing treatments.
Casodex what is
Casdex, czsodex, cawodex, casod4x, casodfx, cazodex, casosex, casoeex, casod3x, caaodex, dasodex, casodexx, casocex, acsodex, caspdex, casidex, casldex, vasodex, caodex, cadodex, casoodex, casoddx, caskdex, casodeex, casdoex, casoxex, csodex, cxsodex, cqsodex.
|
